[go: up one dir, main page]

CA2378982A1 - Procedes permettant d'inhiber l'amyotrophie - Google Patents

Procedes permettant d'inhiber l'amyotrophie Download PDF

Info

Publication number
CA2378982A1
CA2378982A1 CA002378982A CA2378982A CA2378982A1 CA 2378982 A1 CA2378982 A1 CA 2378982A1 CA 002378982 A CA002378982 A CA 002378982A CA 2378982 A CA2378982 A CA 2378982A CA 2378982 A1 CA2378982 A1 CA 2378982A1
Authority
CA
Canada
Prior art keywords
muscle cells
atrophy
raf
ras
mek
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002378982A
Other languages
English (en)
Inventor
David J. Glass
Christian Rommel
George D. Yancopoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2378982A1 publication Critical patent/CA2378982A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne un procédé permettant d'inhiber l'amyotrophie dans les cellules musculaires. L'invention concerne également un procédé permettant d'inhiber l'atrophie du muscle squelettique ou de développer une hypertrophie du muscle squelettique chez les vertébrés. L'invention concerne également un procédé d'identification d'agents, de gènes et de produits génétiques pouvant être utilisés pour réduire la protéolyse ou pour augmenter la protéogenèse dans les cellules musculaires.
CA002378982A 1999-07-07 2000-06-22 Procedes permettant d'inhiber l'amyotrophie Abandoned CA2378982A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14285799P 1999-07-07 1999-07-07
US60/142,857 1999-07-07
PCT/US2000/017173 WO2001004354A2 (fr) 1999-07-07 2000-06-22 Procedes permettant d'inhiber l'amyotrophie

Publications (1)

Publication Number Publication Date
CA2378982A1 true CA2378982A1 (fr) 2001-01-18

Family

ID=22501570

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002378982A Abandoned CA2378982A1 (fr) 1999-07-07 2000-06-22 Procedes permettant d'inhiber l'amyotrophie

Country Status (5)

Country Link
EP (1) EP1192281A2 (fr)
JP (1) JP2003504351A (fr)
AU (1) AU5632300A (fr)
CA (1) CA2378982A1 (fr)
WO (1) WO2001004354A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004526776A (ja) * 2001-04-25 2004-09-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 悪液質を治療するためのファルネシルタンパク質トランスフェラーゼ阻害剤
EP2270196B1 (fr) 2004-05-11 2016-04-20 Axiogenesis Ag Methodes pour la découverte de médicaments utilisant des cellules différentiées in vitro
WO2011018672A1 (fr) * 2008-08-13 2011-02-17 University Of Szeged Methodes et substances destinees a stimuler la regeneration musculaire
US9891232B2 (en) * 2010-11-09 2018-02-13 Sarcotein Diagnostics, Llc BIN1 expression as a marker of skeletal muscle mass and neurological conditions
US9846159B2 (en) 2011-09-30 2017-12-19 Sarcotein Diagnostics, Llc BIN1 expression as a marker of cancer
EP3633381A3 (fr) 2013-12-05 2020-07-29 The Broad Institute, Inc. Compositions et procédés d'identification et de traitement de la cachexie ou de la pré-cachexie
CN107850589B (zh) 2015-03-02 2020-07-24 萨克特恩诊断有限责任公司 13+/17+ bin1表达作为心脏病症的标记
EP3389715A4 (fr) 2015-12-14 2019-06-12 David K. Thomas Compositions et procédés de traitement des dysfonctionnements cardiaques

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444047A (en) * 1994-06-16 1995-08-22 Dipasquale; Gene Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I
EP0934270A1 (fr) * 1996-05-30 1999-08-11 Merck & Co., Inc. Procede de traitement du cancer

Also Published As

Publication number Publication date
JP2003504351A (ja) 2003-02-04
WO2001004354A3 (fr) 2001-08-16
EP1192281A2 (fr) 2002-04-03
AU5632300A (en) 2001-01-30
WO2001004354A2 (fr) 2001-01-18

Similar Documents

Publication Publication Date Title
Patel et al. The function of Myostatin and strategies of Myostatin blockade—new hope for therapies aimed at promoting growth of skeletal muscle
US20060035849A1 (en) Methods and composition for modulating type I muscle formation using pgc-1 alpha
CA2378982A1 (fr) Procedes permettant d'inhiber l'amyotrophie
Lee et al. Functional replacement of myostatin with GDF-11 in the germline of mice
US20020123456A1 (en) Methods of identifying agents affecting atrophy and hypertrophy
US6916603B2 (en) Methods of using agents that modulate bone formation and inhibit adipogenesis
US6548739B2 (en) Method for activating peroxisome proliferator activated receptor-γ
AU777546C (en) Methods of inhibiting atrophy or promoting hypertrophy
Gu et al. Targeted over-expression of PPARγ in pig skeletal muscle improves oxidative fiber formation and intramuscular fat deposition
AU779476B2 (en) Modulation of angiogenesis
JP2002051786A (ja) 骨・軟骨形成組織特異的なプロモーター及びその利用
US20040093625A1 (en) Transgenic or recombinant non-human mammals and their uses in screening psychoactive medicines
Chen Muscle Fiber Hyperplasia in Leg Muscle of Transgenic Quail Overexpressing an Alternative Splicing Variant of Myostatin
Handschin et al. regulates the neuromuscular junction program and α PGC-1
JP2003169679A (ja) ヒトβ３受容体発現動物
JP2007223939A (ja) エネルギー代謝促進因子としてのｈｂ−ｅｇｆの使用
WO1999051983A1 (fr) Procede d'identification d'agents bloqueurs de l'atrophie musculaire

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20050622